Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
Winter JN, Lazarus HM, Rademaker A, Villa M, Mangan C, Tallman M, Jahnke L, Gordon L, Newman S, Byrd K, Cooper BW, Horvath N, Crum E, Stadtmauer EA, Conklin E, Bauman A, Martin J, Goolsby C, Gerson SL, Bender J, O'Gorman M. Winter JN, et al. Among authors: stadtmauer ea. J Clin Oncol. 1996 Jan;14(1):277-86. doi: 10.1200/JCO.1996.14.1.277. J Clin Oncol. 1996. PMID: 8558209 Clinical Trial.
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.
Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL Jr, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM. Antman KH, et al. Among authors: stadtmauer ea. J Clin Oncol. 1997 May;15(5):1870-9. doi: 10.1200/JCO.1997.15.5.1870. J Clin Oncol. 1997. PMID: 9164197
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer.
Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, Reed E, Pelz CJ, Klein JP, Sobocinski KA, Kennedy MJ, Freytes CO, McCarthy PL Jr, Herzig RH, Stadtmauer EA, Lazarus HM, Pecora AL, Bitran JD, Wolff SN, Gale RP, Armitage JO, Vaughan WP, Spitzer G, Horowitz MM. Rowlings PA, et al. Among authors: stadtmauer ea. JAMA. 1999 Oct 13;282(14):1335-43. doi: 10.1001/jama.282.14.1335. JAMA. 1999. PMID: 10527180
Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination.
Stadtmauer EA, Tsai DE, Sickles CJ, Mick R, Luger SM, Porter DL, Mangan PA, Schuchter LM, Schuster SJ, Loh EY, Magee DA, Sachs RA, Wall ME, Moore J, Buzby GP, Zaleta E, Kamoun M, Silberstein LE. Stadtmauer EA, et al. Med Oncol. 1999 Dec;16(4):279-88. doi: 10.1007/BF02785874. Med Oncol. 1999. PMID: 10618691 Clinical Trial.
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH. Stadtmauer EA, et al. N Engl J Med. 2000 Apr 13;342(15):1069-76. doi: 10.1056/NEJM200004133421501. N Engl J Med. 2000. PMID: 10760307 Free article. Clinical Trial.
Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor.
Schenkein DP, Koc Y, Alcindor T, Stadtmauer EA, Miller KB, Cooper BW, Partridge AH, Lazarus HM. Schenkein DP, et al. Among authors: stadtmauer ea. Biol Blood Marrow Transplant. 2000;6(4A):448-55. doi: 10.1016/s1083-8791(00)70037-1. Biol Blood Marrow Transplant. 2000. PMID: 10975514 Clinical Trial.
254 results